XML 98 R68.htm IDEA: XBRL DOCUMENT v3.23.1
Subsequent Event - Additional Information (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 12 Months Ended
Feb. 06, 2023
Feb. 14, 2022
Feb. 09, 2022
May 20, 2021
Mar. 31, 2023
Dec. 31, 2022
Dec. 31, 2021
Subsequent Event [Line Items]              
Payments of offering costs           $ 0 $ 2,765
Common Class A [Member]              
Subsequent Event [Line Items]              
Stock shares issued during the period new issues shares   748,959         5,002,500
Sale of stock net consideration received on the transaction     $ 80,000        
Payments of offering costs           $ 200  
Common Class A [Member] | Over-Allotment Option              
Subsequent Event [Line Items]              
Stock shares issued during the period new issues shares       652,500      
Subsequent Event              
Subsequent Event [Line Items]              
Sale of stock net consideration received on the transaction $ 107,600            
Underwriting Discounts and Commissions 6,900            
Payments of offering costs $ 500            
Subsequent Event | Common Class A [Member]              
Subsequent Event [Line Items]              
Sale of Stock, Number of Shares Issued in Transaction 16,428,572            
Sale of Stock, Price Per Share $ 7.00            
Subsequent Event | Common Class A [Member] | Over-Allotment Option              
Subsequent Event [Line Items]              
Stock shares issued during the period new issues shares 2,142,857            
Revolving Credit Facility [Member] | Subsequent Event              
Subsequent Event [Line Items]              
Debt facility payments description         In March 2023, upon achievement of a clinical data milestone, the Company elected to extend the Loan Facility maturity by 12 months, from December 2026 to December 2027. The interest-only payment period was also extended by 12 months to December 2026.    
Prepayment of the loan         5.00%    
Extended maturity date         7.00%